CURE-PE: A Promising New Treatment for Preterm Pre-Eclampsia

Pre-eclampsia is a common complication associated with significant maternal and perinatal morbidity and mortality worldwide. Although improvements have occurred in prediction, prevention, and management, its pathophysiology remains poorly understood and no cure exists. Management aims to achieve blood pressure control and minimise complications for the mother and the child. It often requires preterm delivery of the baby to keep the mother safe. We have been working closely with a pharmaceutical company from the United States (Comanche Biopharma) to test a new promising drug (single dose subcutaneous injection) that reduces the RNA transcription of soluble Soluble fms-like tyrosine kinase-1 (sFlt-1), an anti-angiogenic protein that inhibits placental growth factor (PlGF) and plays a major role in disease development. We will recruit for the pharmacokinetics studies and trials to evaluate the potential of this new drug as a possible cure for early-onset pre-eclampsia